In vitro-in vivo investigation of the hepatic extraction of RSD1070: a novel antiarrhythmic compound

Purpose. The hepatic extraction of a novel antiarrhythmic, RSD1070, was investigated to test the hypothesis that its poor bioavailability observed in rats is due to high hepatic metabolism. Methods. The pharmacokinetics of RSD1070 was examined in rats (n=8) and its metabolism was investigated usi...

Full description

Bibliographic Details
Main Author: Tong, Vincent Wai-Yip
Format: Others
Language:English
Published: 2009
Online Access:http://hdl.handle.net/2429/10470
id ndltd-UBC-oai-circle.library.ubc.ca-2429-10470
record_format oai_dc
spelling ndltd-UBC-oai-circle.library.ubc.ca-2429-104702018-01-05T17:35:20Z In vitro-in vivo investigation of the hepatic extraction of RSD1070: a novel antiarrhythmic compound Tong, Vincent Wai-Yip Purpose. The hepatic extraction of a novel antiarrhythmic, RSD1070, was investigated to test the hypothesis that its poor bioavailability observed in rats is due to high hepatic metabolism. Methods. The pharmacokinetics of RSD1070 was examined in rats (n=8) and its metabolism was investigated using parent compound disappearance studies in pooled rat hepatic microsome incubations. The free fraction in plasma and microsomal matrices was determined by equilibrium dialysis. Hepatic extraction was predicted from the scaling-up of the microsomal kinetic data using the well-stirred liver model. Results. RSD1070 pharmacokinetics demonstrated a three-compartment model following single iv bolus administration of a dose of 12 mg/kg. RSD1070 exhibited a rapid elimination t1/2 (25 ± 8 min) and a CLtot of 71 ± 9 mL/min/kg. Renal clearance based on 24-hour urinary recovery was determined to be insignificant ( « 1% of CLtot). A Michaelis-Menten model described the consumption of RSD1070 with a Km of 0.45 μg/mL and Vmax of 2.81 μg/min/mg microsomal protein. The in vitro half-life approach examined the first-order consumption rate of RSD1070 (1 μM) in microsomal incubation. Taking the Vmax/Km ratio (CLint) and the in vitro t1/2 as the basis for scaling, the data from the microsomal kinetic studies (75 mL/min/kg) closely approximated the apparent CLtot. Required for the scale-up of in vitro CLint, plasma free fraction (1.5 %) and microsomal free fraction (15 %) were determined and incorporated into the well-stirred liver model. Conclusion. RSD1070 is a high hepatic extraction compound (E = 0.94) with a predicted in vitro CLh value that accounted for the CLtot observed in rats. [Scientific formulae used in this abstract could not be reproduced.] Pharmaceutical Sciences, Faculty of Graduate 2009-07-09T17:48:13Z 2009-07-09T17:48:13Z 2000 2000-05 Text Thesis/Dissertation http://hdl.handle.net/2429/10470 eng For non-commercial purposes only, such as research, private study and education. Additional conditions apply, see Terms of Use https://open.library.ubc.ca/terms_of_use. 4754458 bytes application/pdf
collection NDLTD
language English
format Others
sources NDLTD
description Purpose. The hepatic extraction of a novel antiarrhythmic, RSD1070, was investigated to test the hypothesis that its poor bioavailability observed in rats is due to high hepatic metabolism. Methods. The pharmacokinetics of RSD1070 was examined in rats (n=8) and its metabolism was investigated using parent compound disappearance studies in pooled rat hepatic microsome incubations. The free fraction in plasma and microsomal matrices was determined by equilibrium dialysis. Hepatic extraction was predicted from the scaling-up of the microsomal kinetic data using the well-stirred liver model. Results. RSD1070 pharmacokinetics demonstrated a three-compartment model following single iv bolus administration of a dose of 12 mg/kg. RSD1070 exhibited a rapid elimination t1/2 (25 ± 8 min) and a CLtot of 71 ± 9 mL/min/kg. Renal clearance based on 24-hour urinary recovery was determined to be insignificant ( « 1% of CLtot). A Michaelis-Menten model described the consumption of RSD1070 with a Km of 0.45 μg/mL and Vmax of 2.81 μg/min/mg microsomal protein. The in vitro half-life approach examined the first-order consumption rate of RSD1070 (1 μM) in microsomal incubation. Taking the Vmax/Km ratio (CLint) and the in vitro t1/2 as the basis for scaling, the data from the microsomal kinetic studies (75 mL/min/kg) closely approximated the apparent CLtot. Required for the scale-up of in vitro CLint, plasma free fraction (1.5 %) and microsomal free fraction (15 %) were determined and incorporated into the well-stirred liver model. Conclusion. RSD1070 is a high hepatic extraction compound (E = 0.94) with a predicted in vitro CLh value that accounted for the CLtot observed in rats. [Scientific formulae used in this abstract could not be reproduced.] === Pharmaceutical Sciences, Faculty of === Graduate
author Tong, Vincent Wai-Yip
spellingShingle Tong, Vincent Wai-Yip
In vitro-in vivo investigation of the hepatic extraction of RSD1070: a novel antiarrhythmic compound
author_facet Tong, Vincent Wai-Yip
author_sort Tong, Vincent Wai-Yip
title In vitro-in vivo investigation of the hepatic extraction of RSD1070: a novel antiarrhythmic compound
title_short In vitro-in vivo investigation of the hepatic extraction of RSD1070: a novel antiarrhythmic compound
title_full In vitro-in vivo investigation of the hepatic extraction of RSD1070: a novel antiarrhythmic compound
title_fullStr In vitro-in vivo investigation of the hepatic extraction of RSD1070: a novel antiarrhythmic compound
title_full_unstemmed In vitro-in vivo investigation of the hepatic extraction of RSD1070: a novel antiarrhythmic compound
title_sort in vitro-in vivo investigation of the hepatic extraction of rsd1070: a novel antiarrhythmic compound
publishDate 2009
url http://hdl.handle.net/2429/10470
work_keys_str_mv AT tongvincentwaiyip invitroinvivoinvestigationofthehepaticextractionofrsd1070anovelantiarrhythmiccompound
_version_ 1718588561010196480